Extended-Spectrum β-Lactamase-Producing Escherichia coli in Neonates and Listeria monocytogenes in Young Children with Bacterial Meningitis in Japan

Munehiro Furuichi; Mizuki Yaginuma; Masayoshi Shinjoh; Takuma Ohnishi; Takao Takahashi; Satoshi Iwata

doi:10.1093/jpids/piac135

Extended-Spectrum β-Lactamase-Producing Escherichia coli in Neonates and Listeria monocytogenes in Young Children with Bacterial Meningitis in Japan

J Pediatric Infect Dis Soc. 2023 Apr 18;12(3):165-168. doi: 10.1093/jpids/piac135.

Authors

Munehiro Furuichi¹, Mizuki Yaginuma¹, Masayoshi Shinjoh¹, Takuma Ohnishi¹, Takao Takahashi¹, Satoshi Iwata²

Affiliations

¹ Department of Pediatrics, Keio University School of Medicine, Tokyo, Japan.
² Department of Infectious Diseases, National Cancer Center Hospital, Tokyo, Japan.

PMID: 36525391
DOI: 10.1093/jpids/piac135

Abstract

Nationwide surveillance of pediatric bacterial meningitis in Japan from 2019 to 2021 revealed two uncommon situations not covered by the recommended empiric treatment that were not rare in Japan, namely, extended-spectrum β-lactamase-producing-producing Escherichia coli in neonates and Listeria monocytogenes in children older than 1 month.

Keywords: Listeria monocytogenes; ESBL-producing Escherichia coli; bacterial meningitis; empiric treatment; guideline.

© The Author(s) 2022. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

MeSH terms

Anti-Bacterial Agents / therapeutic use
Child
Child, Preschool
Escherichia coli
Escherichia coli Infections* / microbiology
Humans
Infant
Infant, Newborn
Japan / epidemiology
Listeria monocytogenes*
Meningitis, Bacterial* / drug therapy
beta-Lactamases

Substances

beta-Lactamases
Anti-Bacterial Agents